New Zealand markets open in 7 hours 29 minutes

BIIB Jan 2024 270.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
48.000.00 (0.00%)
As of 11:23AM EDT. Market open.
Full screen
Previous close48.00
Open48.00
Bid0.00
Ask0.00
Strike270.00
Expiry date2024-01-19
Day's range48.00 - 48.00
Contract rangeN/A
Volume1
Open interest13
  • Motley Fool

    Is Eli Lilly Stock a Buy Following This Competitor's Major Win?

    Eli Lilly (NYSE: LLY) was already having a great year in the stock market, but on Sept. 28, the company's shares jumped by about 7%. The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab. Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too.

  • Zacks

    Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?

    AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.

  • Zacks

    Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?

    Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.